Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Crescent Biopharma, retaining the price target of $25.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Crescent Biopharma’s promising future. The company’s CR-001, a PD-1 x VEGF bispecific antibody, is poised to benefit from the successful outcomes of the HARMONi-A trial, where ivonescimab showed significant overall survival benefits in specific cancer types. This positions Crescent Biopharma for rapid advancement into clinical trials, especially given the molecule’s similarity to ivonescimab, which has already demonstrated superior progression-free survival compared to other treatments.
Additionally, Crescent Biopharma’s strong intellectual property position, with patents extending to 2045, provides a robust defense for its innovative portfolio. The proprietary engineering of CR-001 enhances its stability and manufacturability, potentially allowing for future subcutaneous dosing. The preclinical results presented at the SITC 2025 conference further support CR-001’s potential, showing significant anti-tumor activity and strong receptor occupancy. These factors, combined with Crescent’s undervaluation compared to peers, underpin Kapoor’s Buy rating and the optimistic price target.
In another report released on November 6, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.